Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$313.7863
11.29(3.6%)
as of July 15, 2025
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
313.7863
Open
325.0766
High
325.0766
Low
308.9113
52 wk Range
200.63-377.46
Market Cap
7 102 M
Shares Outstanding
22 203 K
Revenue
317 M
EPS
-3.32
Beta
-1.082
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 317 M
- EBITDA: -423 841 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -6.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
High Growth Tech Stocks To Watch In US July 2025
The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can...
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's strong launch propels stock outlook
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biotechnology sector with its flagship drug Rezdiffra, a treatment for nonalcoholic steatohepatitis (NASH). With a market capi...
Madrigal Pharmaceuticals stock to be featured in comparative analysis at upcoming conference
Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta-anal...
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their Mark...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
